451-71-8

Basic information

• Product Name: Glyhexamide
• Synonyms: Glyhexamide;N-[(Cyclohexylamino)carbonyl]-2,3-dihydro-1H-indene-5-sulfonamide;NSC-106960;SQ-15860;1-cyclohexyl-3-(2,3-dihydro-1H-inden-5-ylsulfonyl)urea;1-cyclohexyl-3-indan-5-ylsulfonyl-urea
• CAS NO: 451-71-8
• Molecular Formula: C16H22N2O3S
• Molecular Weight: 322.427
• Mol File: 451-71-8.mol
• Article Data: 2

Chemical Properties

• Melting Point: 153-155°
• Boiling Point: °Cat760mmHg
• Flash Point: °C
• Appearance: /
• Density: 1.3g/cm³
• Refractive Index: 1.602
• PKA: 5.28±0.20(Predicted)
• CAS DataBase Reference: Glyhexamide(CAS DataBase Reference)
• NIST Chemistry Reference: Glyhexamide(451-71-8)
• EPA Substance Registry System: Glyhexamide(451-71-8)

Safety Data

• Hazardous Substances Data: 451-71-8(Hazardous Substances Data)

Usage

General Description

Glyhexamide is an oral antidiabetic medication that belongs to the class of drugs known as sulfonylureas. It works by stimulating the release of insulin from the pancreas and increasing the sensitivity of body tissues to insulin, thereby helping to lower blood sugar levels in people with type 2 diabetes. Glyhexamide is often prescribed as a second-line treatment for diabetes when diet and exercise alone are not sufficient to control blood sugar levels. It is available in tablet form and is typically taken once or twice daily with meals. Side effects may include low blood sugar, weight gain, and gastrointestinal upset, and it is important for people taking Glyhexamide to monitor their blood sugar levels regularly and to be aware of potential interactions with other medications.

InChI:InChI=1/C16H22N2O3S/c19-16(17-14-7-2-1-3-8-14)18-22(20,21)15-10-9-12-5-4-6-13(12)11-15/h9-11,14H,1-8H2,(H2,17,18,19)

Relevant articles and documents

Combinations comprising dipeptidylpeptidase-iv inhibitor

The invention relates to a combination which comprises a DPP-IV inhibitor and at least one further antidiabetic compound, preferably selected from the group consisting of insulin signalling pathway modulators, like inhibitors of protein tyrosine phosphatases (PTPases), non-small molecule mimetic compounds and inhibitors of glutamine-fructose-6-phosphate amidotransferase (GFAT), compounds influencing a dysregulated hepatic glucose production, like inhibitors of glucose-6-phosphatase (G6Pase), inhibitors of fructose-1,6-bisphosphatase (F-1,6-BPase), inhibitors of glycogen phosphorylase (GP), glucagon receptor antagonists and inhibitors of phosphoenolpyruvate carboxykinase (PEPCK), pyruvate dehydrogenase kinase (PDHK) inhibitors, insulin sensitivity enhancers, insulin secretion enhancers, α-glucosidase inhibitors, inhibitors of gastric emptying, insulin, and α2-adrenergic antagonists, for simultaneous, separate or sequential use in the prevention, delay of progression or treatment of conditions mediated by dipeptidylpeptidase-IV (DPP-IV), in particular diabetes, more especially type 2 diabetes mellitus, conditions of impaired glucose tolerance (IGT), conditions of impaired fasting plasma glucose, metabolic acidosis, ketosis, arthritis, obesity and osteoporosis; and the use of such combination for the cosmetic treatment of a mammal in order to effect a cosmetically beneficial loss of body weight.